Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

  • days left to enroll
  • participants needed
  • sponsor
    Shi Yanxia
Updated on 26 March 2022


This study aims to investigate the efficacy and safety of olanzapine combined with fosaprepitant, ondansetron and dexamethasone compared with placebo combined with fosaprepitant, ondansetron and dexamethasone in the prevention of nausea and vomiting in germ-cell tumors receiving 5-day cisplatin chemotherapy


This is a prospective, randomized, double-blind, placebo-controlled, cross-over Phase III clinical study.

A total of 75 patients were enrolled in two sequential treatment groups (olanzapine-placebo and placebo-Olanzapine).

(1) The screening process begins after the patient signs the written informed consent. (2) Patients were randomly divided into control group (placebo) and experimental group (olanzapine). (3) Patients' effectiveness from the beginning of chemotherapy drug infusion (0 h on day 1) to day 10 (approximately 240 h) was monitored by patients' diary from 2 to 10 days after chemotherapy, in which patients should report episodes of vomiting in the previous 24 hours, use of remedial therapy, and assessment of daily nausea. Any episodes of vomiting or retching, as well as the time and date of use of rescue medications, should also be recorded. At days 2 to 6, patients were assessed on the visual analog scale (VAS) for the previous 24 hours. (4) The Hospital Anxiety and Depression Scale (HADS),and Life Index - Vomiting (FLIE) questionnaire of days 1-10 should be completed immediately after the log is completed on day 10. (5) During the study period, patients may receive "remedial treatment" for nausea or vomiting, and patients requiring remedial treatment are considered to have failed treatment because the primary endpoint is complete remission. However, patients receiving remedial treatment must continue to receive the study drug and complete the diary as directed.

Condition Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin
Treatment Placebo, Olanzapine Tablets
Clinical Study IdentifierNCT05244577
SponsorShi Yanxia
Last Modified on26 March 2022


Yes No Not Sure

Inclusion Criteria

Patients must meet the following criteria for inclusion
Pathology confirmed germ cell tumor (both spermatogonoma and non-spermatogonoma) and had no chemotherapy before
Age ≥16 years old
ECOG score of physical status 0-2
Chemotherapy regimen containing 5-day cisplatin (20mg/m2, 100mg total
No other nausea, vomiting, or use of any antiemetics within 72 hours prior to enrollment
There are no clear brain metastases or other reasons for long-term systemic use of hormones
The general condition is good, and the blood, liver and kidney functions meet the following standards
Hemoglobin: 90 g/L and above White blood cell count: 3.5 109 / L - 10.0 _109
L Neutrophil count: 1.5_ 109/L or above Platelet count: 90 109/L or above
Serum total bilirubin: below 1.5 times the upper limit of normal Serum AST
ALT and ALP: the upper limit of normal is below 2.5 times when the patient is
Ability to read, understand and complete research questionnaires and journals, including visual analog scale (VAS)
Understand the study procedure and sign the informed consent in person to participate in the study

Exclusion Criteria

Patients who meet any of the following criteria will be excluded
Digestive tract obstruction, water and electrolyte disorder
Have central nervous system diseases (such as primary brain tumors, uncontrolled seizures, any history of brain metastases or strokes)
Contraindications to the use of glucocorticoids: ① Viral, bacterial, fungal and other infections that cannot be controlled by antibiotics;② Active gastric or duodenal ulcer;③ Severe hypertension, arteriosclerosis, diabetes; ④ Osteoporosis;⑤ Corneal ulcer;⑥Trauma or surgical repair period, fracture; ⑦Adeno-cortical hyperfunction; ⑧Severe mental illness and epilepsy; ⑨ patients with cardiac or renal dysfunction
Patients with mental disabilities or severe emotional or mental disorders are considered unsuitable for inclusion in the study
In addition to malignancy, the patient has an active infection (e.g. pneumonia, hepatitis) or any uncontrolled infection diseases (such as diabetic ketoacidosis), and the researchers believe may contribute to the study's findings confounding, or exposing patients receiving study drugs to unnecessary risks
The patient is currently using any prohibited drugs, including medicinal marijuana or is currently using alcohol (Chinese Diagnostic criteria for drug dependence)
The patient received an unapproved (experimental) drug treatment within the past 4 weeks
Taking oral olanzapine or other psychotropic drugs
A history of hypersensitivity to fosappitan, 5-HT3 receptor antagonists or dexamethasone
The patient cannot swallow the drugs
The principal investigator considered the patients unsuitable for the study
Inability or unwillingness to adhere to research protocols
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note